01 8Nucala
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 1,378
2019 Revenue in Millions : 1,065
Growth (%) : 29
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 1,545
2020 Revenue in Millions : 1,362
Growth (%) : 15
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 1,754
2021 Revenue in Millions : 1,545
Growth (%) : 14
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 1,786
2022 Revenue in Millions : 1,754
Growth (%) : 16
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 126
2015 Revenue in Millions : 2
Growth (%) : 6,200
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 485
2016 Revenue in Millions : 144
Growth (%) : 237
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 749
2017 Revenue in Millions : 458
Growth (%) : 63%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 952
2018 Revenue in Millions : 698
Growth (%) : 36
